{"result": "(\"entity\"<|>COCHRANE LIBRARY<|>ORGANIZATION<|>The Cochrane Library is a collection of databases that provide systematic reviews of healthcare interventions, including studies on nutritional supplements and their effects on patients.)\n##\n(\"entity\"<|>ARGININE<|>PERSON<|>Arginine is a conditionally essential amino acid known for its immunomodulatory effects, particularly in stimulating T lymphocyte activity and reducing pro-inflammatory cytokines.)\n##\n(\"entity\"<|>GLUTAMINE<|>PERSON<|>Glutamine is another conditionally essential amino acid that decreases in severe illness and has shown benefits in reducing infections and complications in abdominal surgery patients.)\n##\n(\"entity\"<|>HMB<|>PERSON<|>HMB, or ß-hydroxy-ß-methyl butyrate, is a metabolite of leucine used as a dietary supplement to increase strength and muscle mass, particularly in resistance training.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to the provision of nutrients to patients who are malnourished or unable to consume food through the digestive tract, often used in conjunction with cancer treatment.)\n##\n(\"entity\"<|>SARCOPENIA<|>EVENT<|>Sarcopenia is the primary characteristic of cancer cachexia, marked by anabolic resistance that hinders the incorporation of amino acids into muscle.)\n##\n(\"relationship\"<|>COCHRANE LIBRARY<|>ARGININE<|>The Cochrane Library conducted systematic reviews that include studies on the effects of arginine on patients, particularly in cancer care<|>7)\n##\n(\"relationship\"<|>COCHRANE LIBRARY<|>GLUTAMINE<|>The Cochrane Library has reviewed studies that document the benefits of glutamine supplementation in surgical patients<|>7)\n##\n(\"relationship\"<|>ARGININE<|>GLUTAMINE<|>Both arginine and glutamine are conditionally essential amino acids that have been studied for their roles in immune function and patient recovery<|>5)\n##\n(\"relationship\"<|>HMB<|>SARCOPENIA<|>HMB is used as a dietary supplement to combat sarcopenia by minimizing muscle loss and enhancing strength<|>8)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>SARCOPENIA<|>Nutritional support is indicated for patients suffering from sarcopenia, particularly those undergoing cancer treatment<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: rdida de peso y promoviendo la recu-\nperación ponderal. Se han realizado numerosos estu-\ndios con resultados contradictorios, por lo que la bi-\nblioteca Cochrane realizó una revisión sistemática\npublicada en 200737. En dicha revisión se concluye que\nno parece haber una mejoría significativa en el trata-\nmiento de síntomas con los suplementos enriquecidos\ncon omega-3, con respecto a aquella obtenida de los\npacientes que reciben un suplemento nutricional con\naltos contenidos de calorías y proteínas. Incluso parece\nque si se asocia con acetato de megestrol, se podría\nreducir la eficacia de este. Sin embargo, varios ensayos\nclínicos, han documentado efectos beneficiosos sobre\ntodo en los pacientes en quimioterapia, logrando una\nmejoría en composición corporal, apetito, morbilidad y\ncalidad de vida. La evidencia actual no permite hacer\nrecomendaciones, pero en caso de emplearlo, los be-\nneficios se han obtenido con dosis de al menos 2 g/día.\n\nArginina: es un aminoácido condicionalmente esen-\ncial, con efectos inmunomoduladores, como estimular\nla actividad de los linfocitos T o las células natural killer\ny disminuir los niveles de citocinas proinflamatorias. El\nhecho de que la L-arginina sea precursor del óxido ní-\ntrico ha llevado a investigar su papel en diferentes pa-\ntologías, entre ellas el cáncer. En pacientes oncológicos\nquirúrgicos ha demostrado una reducción de las infec-\nciones y el tiempo de ingreso, por lo que las principales\nsociedades de nutrición apoyan el empleo de fórmulas\nenriquecidas con arginina en estas situaciones38.\n\nGlutamina: aminoácido también condicionalmente\nesencial. Sus niveles descienden en caso de enfermedad\ngrave, aunque no se ha probado que esto se deba a un\nagotamiento de las reservas. Su suplementación perio-\nperatoria, ha demostrado una disminución de infeccio-\nnes y complicaciones postoperatorias de pacientes so-\nmetidos a cirugía abdominal, con una reducción de la\nestancia media39. Sus principales efectos beneficiosos se\nhan demostrado cuando se administra en NPT. Se ha\nespeculado sobre el papel que puede desempeñar en la\nestabilización de la membrana celular de las células tu-\nmorales, protegiéndolas contra la acidificación, ya que\nestas incorporan y metabolizan la glutamina rápida-\nmente. Además, la glutamina participa en otros muchos\nprocesos metabólicos y hasta que queden claramente\nesclarecidos sus efectos parece prudente no recomendar\nla suplementación con glutamina a largo plazo.\n\nNucleótidos: en la leche materna existen abundantes\nnucleótidos y probablemente sean inmunomodulado-\nres en lactantes. En humanos, no existen estudios que\n\ndemuestren que añadidos a la dieta tengan efectos\nbeneficiosos, pero en experimentos animales sí han de-\nmostrado una mejoría de la respuesta inmune, por lo\nque son componente habitual de las fórmulas inmuno-\nmoduladoras32.\n\nOtros componentes especiales sin acción inmuno-\nmoduladora: leucina o HMB.\n\nLa sarcopenia es la característica principal de la ca-\nquexia oncológica, debido a la presencia de resistencia\nanabólica, se dificulta la incorporación de aminoácidos al\nmúsculo. El ß-hidroxi-ß-metil butirato (HMB) es un meta-\nbolito de la leucina que se emplea como suplemento\ndietético para aumentar la fuerza y la masa muscular en\nel entrenamiento de resistencia, minimizando la pérdida\nmuscular por sus efectos anticatabólicos. Con estas pre-\nmisas se ha incorporado a SNO para mejorar la sarcope-\nnia. Sus efectos sí se han documentado en pacientes sa-\nnos, pero en pacientes ancianos y enfermos no existen\ndatos que permitan hacer recomendaciones para su uso21.\n\n6.5.3. Nutrición parenteral\n\nSu uso estaría indicado en aquellos pacientes malnu-\ntridos, candidatos a tratamiento antitumoral que no son\ncandidatos a recibir NE, por tracto digestivo no funcio-\nnante o estando normonutridos que no pueden utilizar\nel tracto digestivo durante un periodo prolongado.\n\nLa NP puede administrarse por vía periférica si se to-\nlera un aporte hídrico elevado o si se emplea como re-\nfuerzo de otro tipo de nutrición. Para soportes nutri-\ncionales que se prolonguen más de una semana, es\npreferible la utilización de accesos centrales.\n\nAunque existen fórmulas comerciales, se debe formu-\nlar la composición\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}